An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System

Kathryn Marwitz, S. Christopher Jones, Cindy M. Kortepeter, Gerald J. Dal Pan and Monica A. Muñoz ()
Additional contact information
Kathryn Marwitz: Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US FDA
S. Christopher Jones: Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US FDA
Cindy M. Kortepeter: Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US FDA
Gerald J. Dal Pan: Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US FDA
Monica A. Muñoz: Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US FDA

Drug Safety, 2020, vol. 43, issue 5, No 6, 457-465

Abstract: Abstract Introduction Adverse reactions with an outcome of death are inherently important for pharmacovigilance organizations to evaluate. Prior efforts to systematically evaluate individual case safety reports (ICSRs) with an outcome of death have been limited to high-level summaries. Objective The aim of this study was to characterize ICSRs with an outcome of death contained in the US FDA Adverse Event Reporting System (FAERS) database. Methods All ICSRs received through 31 December 2017 reporting an outcome of death were characterized by patient demographics, suspect product(s), adverse events, and reporter type. Using the ICSR’s narrative and reporter information, we classified ICSRs by source to include those from industry-sponsored programs, poison control centers, specialty pharmacies, and litigation. Additionally, a random sample of ICSRs was evaluated for completeness of structured data fields and manually reviewed for the availability of key information in the narrative (i.e. cause of death, medical history, and causality assessment). Results Overall, 1,053,716 ICSRs with a death outcome were received in the study period. Ten medications treating conditions for malignancies, pain, and kidney disease accounted for nearly 20% of all fatal ICSRs. ICSRs originating from industry-sponsored programs, poison control centers, litigation, and specialty pharmacies accounted for 14%, 6.5%, 5.0%, and 3.3% of all fatal ICSRs, respectively. ICSRs in which the only adverse event coded was ‘death’ were more likely to be missing structured data and less likely to include key information in the narrative. Conclusion Understanding the origins and characteristics of ICSRs with an outcome of death supports meaningful evaluations and interpretations of FAERS data. A wide variability in ICSR quality exists, even in those reports with the most serious outcome.

Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-020-00908-5 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:43:y:2020:i:5:d:10.1007_s40264-020-00908-5

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-020-00908-5

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().